Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512252 · ClinicalTrials.gov registry record · Phase 1
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT00512252 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 52 participants.
The verdict
NCT00512252, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study is a phase I/II study to determine the safety and efficacy of AMD3100 when combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory AML. We hypothesize that disrupting the interaction between AML blasts and the marrow microenvironment with AMD3100 may enhance the cytotoxic effect of chemotherapy.
Interventions
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Mitoxantrone
- DRUG AMD3100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00512252
The ClinicalTrials.gov registry entry for NCT00512252 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Etoposide is the first listed.
NCT00512252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00512252 about?
NCT00512252 is a clinical study titled "AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia". This study is a phase I/II study to determine the safety and efficacy of AMD3100 when combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory AML. We hypothesize that disrupting the interaction between AML blasts and the marrow microenvironment with AMD3100 may...
What is the current status of trial NCT00512252?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2007-07. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00512252?
The interventions under investigation include: Etoposide (DRUG), Cytarabine (DRUG), Mitoxantrone (DRUG), AMD3100 (DRUG).
Who is sponsoring clinical trial NCT00512252?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.